Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

Axogen Inc. achieved a 52-week high after the FDA approved its Avance Nerve Graft for treating peripheral nerve discontinuities. The graft uses processed human nerve tissue from cadavers, avoiding the need for a second surgical site. Axogen's Q3 revenue rose 23.5% to $60.1 million, surpassing expectations. The company raised 2025 revenue guidance and expects positive net cash flow for the year. Shares rose 18.78% to $31.01.